Cost sharing and decreased branded oral anti-diabetic medication adherence among elderly part D medicare beneficiaries

Journal of General Internal Medicine

Volumn 28, Issue 7, 2013, Pages 876-885

  Sacks, Naomi C ^b,c   Burgess Jr , James F ^a,b   Cabral, Howard J ^b   Pizer, Steven D ^b,f   McDonnell, Marie E ^d,e  

^a Center for Organization Leadership and Management Research   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c IQVIA   (United States)

^d BOSTON MEDICAL CENTER   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

coverage gap; diabetes; Medicare; medication adherence; Part D

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ORAL ANTIDIABETIC AGENT;

AGED; ARTICLE; COHORT ANALYSIS; DIABETES MELLITUS; ELDERLY CARE; FEMALE; HEALTH CARE COST; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PRESCRIPTION; RETROSPECTIVE STUDY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; COHORT STUDIES; COST SHARING; DIABETES MELLITUS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MEDICARE PART D; MEDICATION ADHERENCE; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84879556023     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-013-2342-3     Document Type: Article

References (67)

1. Goldman DP, Joyce GF, Escarce JJ, Pace JE, Solomon MD, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291(19):2344- 50.
2. Hsu J, Price M, Huang J, et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med. 2006;354(22):2349-59.
3. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349(23):2224-32.
4. Jackson JE, Doescher MP, Saver BG, Fishman P. Prescription drug coverage, health, and medication acquisition among seniors with one or more chronic conditions. Med Care. 2004;42(11):1056-65.
5. Joyce GF, Escarce JJ, Solomon MD, Goldman DP. Employer drug benefit plans and spending on prescription drugs. JAMA. 2002;288(14):1733-9.
6. Piette JD, Wagner TH, Potter MB, Schillinger D. Health insurance status, cost-related medication underuse, and outcomes among diabetes patients in three systems of care. Med Care. 2004;42(2):102-9.
7. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521-30.
8. Soumerai SB, Ross-Degnan SD, Avorn J, McLauglin T, Choodnovskiu I. Effects of Medicaid drug-payment limits on admissions to nursing homes. N Engl J Med. 1991;325(15):1072-7.
9. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute metal health services by patients with schizophrenia. N Engl J Med. 1994;331(10):650-5.
10. Stuart B, Zacker C. Who bears the burden of Medicaid drug copayment policies? Health Aff (Millwood). 1999;18(2):201-12.
11. Tamblyn R, Laprise R, Hanley JA, Abrahamowicz M, Scott S, Mayo N. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285(4):421-9.
12. Tseng CW, Brook RH, Keeler E, Mangione CM. Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients. JAMA. 2003;290(2):222-7.
13. Tseng CW, Brook RH, Keeler E, Mangione CM. Cost-lowering strategies used by Medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage. JAMA. 2004;292(8):952-60.
14. Donohue JM, Zhang Y, Lave JR. The Medicare drug benefit (Part D) and treatment of heart failure in older adults. Am Heart J. 2010;160(1):159-65.
15. Donohue JM, Zhang Y, Aiju M, Perera S, Lave JR, Hanlon JT, et al. Impact of Medicare Part D on antidepressant treatment, medication choice, and adherence among older adults with depression. Am J Geriatr Psychiatr. 2011;19(12):989-97.
16. Duggan M, Scott Morton F. The effect of Medicare Part D on pharmaceutical prices and utilization. Am Econ Rev. 2010;100(1):590-607.
17. Ketcham JD, Simon KI. Medicare Part D's effects on elderly patients' drug costs and utilization. Am J Manage Care. 2008;14(11 Suppl):SP14-22.
18. Kennedy JJ, Maciejewski M, Liu D, Blodgett E. Cost-related nonadherence in the Medicare program: the impact of Part D. Med Care. 2011;49(5):522-6.
19. Lichtenberg FR, Sun SX. The impact of Medicare Part D on prescription drug use by the elderly. Health Aff (Millwood). 2007;26(6):1735-44.
20. Liu FX, Alexander GC, Crawford SY, Pickard AS, Hedeker D, Walton SM. The impact of Medicare Part D on out-of-pocket costs for prescription drugs, medication utilization, health resource utilization, and preference-based health utility. Health Serv Res. 2011;46(4):1104-23. doi: 10.1111/j.1475-6773.2011. 01273.x. Epub 2011 May 24.
21. Safran D, Strollo MK, Gutterman S, Li A, Rogers WH, Neuman P. Prescription coverage, use and spending before and after Part D implementation: a national longitudinal panel study. J Gen Intern Med. 2010;25(1):10-7. Epub 2009 Oct 31.
22. Schneeweiss S, Patrick AR, Pedan A, Varasteh L, Levin R, Liu N, et al. The effect of Medicare Part D coverage on drug use and cost sharing among seniors without prior drug benefits. Health Aff (Millwood). 2009;28(2):w305-16. Epub 2009 Feb 3.
23. Yin W, Basu A, Zhang JX, Rabbani A, Meltzer DO, Alexander GC. The effect of the Medicare Part D prescription benefit on drug utilization and expenditures. Ann Intern Med. 2008;4(148):169-77. Epub 2008 Jan 7.
24. Zhang Y, Donohue JM, Lave JR, O'Donnell G, Newhouse JP. The effect of Medicare Part D on drug and medical spending. N Engl J Med. 2009;361(1):52-61.
25. Zhang Y, Donohue JM, Newhouse JP, Lave JR. The effects of the coverage gap on drug spending: a closer look at Medicare Part D. Health Aff (Millwood). 2009;28(2):w317-25. Epub 2009 Feb 3.
26. Afendulis CC, He Y, Zaslavsky AM, Chernew ME. The impact of Medicare Part D on hospitalization rates. Health Serv Res. 2011;46(4):1022-38. doi: 10.1111/j.1475-6773.2011.01244.x. Epub 2011 Feb 9.
27. McWilliams JM, Zaslavsky AM, Huskamp HA. Implementation of Medicare Part D and nondrug medical spending for elderly adults with limited prior drug coverage. JAMA. 2011;306(4):402-9.
28. Madden JM, Graves AJ, Ross-Degnan D, Briesacher BA, Soumerai SB. Cost-related medication nonadherence after implementation of Medicare Part D, 2006-2007. JAMA. 2009;302(16):1755-6.
29. Hoadley J, Hargrave E, Cubanski J, Neuman T. The Medicare Part D Coverage Gap: Cost and Consequences 2007. Menlo Park: The Henry J. Kaiser Family Foundation; 2008. http://www.kff.org/medicare/upload/7811.pdf.
30. Kaiser Family Foundation. Understanding the Effects of the Medicare Part D Coverage Gap in 2008 and 2009: Costs and Consequences Prior to Improvements in Coverage Established by the 2010 Health Reform Law. Menlo Park: The Henry J. Kaiser Family Foundation; 2011.
31. Fung V, Mangione CM, Huang J, Turk N, Quiter ES, Schmittdiel JA, et al. Falling into the coverage gap: Part D drug costs and adherence for Medicare advantage prescription drug plan beneficiaries with diabetes. Health Serv Res. 2010;45(2):355-75. Epub 2009 Dec 30.
32. Pedan A, Lu J, Varasteh L. Assessment of drug consumption patterns for Medicare Part D patients. Am J Manage Care. 2009;15(5):323-7.
33. Raebel MA, Delate T, Ellis J, Bayliss EA. Effects of reaching the drug benefit threshold on Medicare members' healthcare utilization during the first year of Medicare Part D. Med Care. 2008;46(10):1116-22.
34. Schmittdiel JA, Ettner SL, Fung V, Huang J, Turk N, Quiter ES, et al. Medicare Part D coverage gap and diabetes beneficiaries. Am J Manage Care. 2009;15(3):189-93.
35. Gellad WF, Donohue JM, Zhao X, Zhang Y, Banthin JS. The financial burden from prescription drugs has declined recently for the nonelderly, although it is still high for many. Health Aff (Millwood). 2012;31(2):408-16.
36. Zhang Y, Gellad WF, Zhou L, Lin YJ, Lave JR. Access to and use of $4 generic programs in Medicare. J Gen Intern Med. 2012 Feb 7 [Epub ahead of print].
37. Atiken M, Berndt E, Cutler D. Prescription drug spending trends in the United States: looking beyond the turning point. Health Aff (Millwood). 2009;28(1):w151-60. Epub 2008 Dec 16.
38. Aitken M, Berndt E. Medicare Part D at age five: what has happened to seniors' prescription drug prices? http://www.imshealth.com/ims/Global/Content/ Home%20Page%20Content/IMS%20News/IHII-Medicare-Part-D2.pdf Accessed January 5, 2013.
39. IMS Institute for Healthcare Informatics. The use of medicines in the United States: a review of 2011. April 2012. http://www.imshealth.com/portal/ site/ims/menuitem.5ad1c081663fdf9b41d84b903208c22a/?vgnextoid= e39f79d7f269e210VgnVCM10000071812ca2RCRD&vgnextfmt=default Accessed January 5, 2013.
40. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):854-65.
41. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166(17):1836-41.
42. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43:521-30.
43. Balkrishnan R, Rajagopalan R, Camacho FT, Huston SA, Murray FT, Anderson RT. Predictors of medication adherence and associated healthcare costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther. 2003;25(11):2958-71.
44. Hong JS, Kang HC. Relationship between oral antihyperglycemic medication adherence and hospitalization, mortality, and healthcare costs in adult ambulatory care patients with type 2 diabetes in South Korea. Med Care. 2011;49(4):378-87.
45. Encinosa WE, Bernard D, Dor A. Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes. Adv Health Econ Health Serv Res. 2010;22:151-73.
46. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). National Diabetes Statistics, 2011. http://diabetes.niddk.nih.gov/dm/pubs/ statistics/DM-Statistics-508.pdf. Accessed January 5, 2013; 2011.
47. Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P, Clinical Guidelines Committee of the American College of Physicians. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2012;156(3):218-31.
48. IMS National Prescription Audit Database, August 2009.
49. Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens. 2008;26(4):819-24.
50. IMS Health Statistical Services, personal communication.
51. Chen J, Ma Q. Comparison of Pharmacy-based and Diagnosis-based Comorbidity Tools. 2010. Unpublished manuscript.
52. Rosenzweig JL, Weinger K, Poirier-Solomon L, Rushton M. Use of a disease severity index for evaluation of healthcare costs and management of comorbidities of patients with diabetes mellitus. Am J Manage Care. 2002;8(11):950-8.
53. Von Korff M, Wagner DH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992;45:197-203.
54. Clark DO, Von Korff M, Saunders K, Baluch WM, Simon GE. A chronic disease score with empirically derived weights. Med Care. 1995;33:783-95.
55. Fishman PA, Shay DK. Development and estimation of a pediatric chronic disease score using automated pharmacy data. Med Care. 1999;37(9):874-83.
56. Gilmer T, Kronick R, Fishman P, Ganiats TG. Pharmacy-based risk adjustment for public programs. Med Care. 2001;39(11):1188-202.
57. Sales AE, Liu CR, Sloan KL, Malkin J, Fishman PA, et al. Predicting costs of care using a pharmacy-based measure risk adjustment in a Veteran population. Med Care. 2003;41(6):753-60.
58. Sloan KL, Sales AE, Liu CF, Fishman P, Nichol P, Suzuki NT, et al. Construction and characteristics of the RxRisk-V: a VA-adapted pharmacy-based case-mix instrument. Med Care. 2003;41(6):761-74.
59. Putnam KG, Buist DS, Fishman P, Andraded SE, Boles M, Chase GA, et al. Chronic disease score as a predictor of hospitalization. Epidemiology. 2002;13(3):340-6.
60. Lamers LM, van Vliet RC. The pharmacy-based Cost Group model: validating and adjusting the classification of medications for chronic conditions to the Dutch situation. Health Policy. 2004;68:113-21.
61. Lamers LM. Risk-adjusted capitation payments: developing a diagnostic cost groups classification for the Dutch situation. Health Policy. 1998;45:15-32.
62. Schneeweiss S, Wang PS, Avorn J, et al. Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res. 2003;38:1103-20.
63. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR, American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-79. Epub 2012 Apr 19.
64. Andrade SE, Kahler KH, Frech F, Chen KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15(8):565-74.
65. Wang V, Liu C, Bryson CL, Sharp ND, Maciejewski ML. Does medication adherence following a copayment increase differ by disease burden? Health Serv Res. 2011;46(6pt1):1963-85. doi: 10.1111/j.1475-6773.2011.01286.x. Epub 2011 Jun 20.
66. Bradley DM, Wiley-Exley EK, Richards S. Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother. 2009;43(1):36-44. Epub 2009 Jan 6.
67. Stuart B, Simoni-Wastila L, Yin X, Davidoff A, Zuckerman IH, Doshi J. Medication use and adherence among elderly Medicare beneficiaries with diabetes enrolled in Part D and retiree health plans. Med Care. 2011;49(5):511-5.